AbbVie Inc. $ABBV Shares Newly Acquired by MFG Investments LLC

MFG Investments LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,760 shares of the company’s stock, valued at approximately $461,000.

Other institutional investors have also modified their holdings of the company. Third View Private Wealth LLC boosted its stake in AbbVie by 9.2% in the 3rd quarter. Third View Private Wealth LLC now owns 4,694 shares of the company’s stock worth $1,228,000 after buying an additional 394 shares during the last quarter. Provenance Wealth Advisors LLC grew its holdings in AbbVie by 697.6% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 12,482 shares of the company’s stock valued at $3,265,000 after buying an additional 10,917 shares during the period. One Day In July LLC increased its stake in shares of AbbVie by 6.9% during the 3rd quarter. One Day In July LLC now owns 3,359 shares of the company’s stock valued at $879,000 after acquiring an additional 216 shares during the last quarter. Hughes Financial Services LLC increased its stake in shares of AbbVie by 9.9% during the 3rd quarter. Hughes Financial Services LLC now owns 719 shares of the company’s stock valued at $188,000 after acquiring an additional 65 shares during the last quarter. Finally, Lyell Wealth Management LP lifted its holdings in shares of AbbVie by 6.6% during the 3rd quarter. Lyell Wealth Management LP now owns 3,859 shares of the company’s stock worth $1,009,000 after acquiring an additional 240 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently issued reports on ABBV. Argus raised their target price on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Scotiabank upped their price target on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. UBS Group increased their price target on shares of AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a research note on Monday. Cantor Fitzgerald increased their price target on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Morgan Stanley lifted their price target on shares of AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $296.88.

AbbVie Price Performance

NYSE ABBV opened at $285.88 on Wednesday. The firm has a market capitalization of $505.09 billion, a P/E ratio of 49.20, a P/E/G ratio of 1.31 and a beta of 0.20. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $298.74. The business’s 50-day simple moving average is $270.23 and its 200-day simple moving average is $237.89.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The firm had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the prior year, the company earned $1.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis. On average, equities research analysts expect that AbbVie Inc. will post 14.00 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s payout ratio is presently 119.10%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.